Navigation Links
Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
Date:1/30/2008


2008 Projected Financial Highlights and Potential Milestones include:

- Grow Zevalin sales

- XYOTAX(TM) Marketing Authorization Application submission in Q1

- Pixantrone phase III results and New Drug Application submission

- Brostallicin phase II interim results

SEATTLE, Jan. 30 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced today that with the return of CTI to a commercial operating company through its acquisition of Zevalin(R) (Ibritumomab Tiuxetan), the company will focus its resources on increasing the sales of Zevalin in the United States and preparing the marketing applications for XYOTAX (paclitaxel poliglumex, CT-2103) and pixantrone (BBR 2778), while supporting the advancement of brostallicin to a phase III trial. The move will reduce the Company's projected net cash operating expenses to a forecasted $77 million in 2008. The primary reduction in operating expenses stems from deferring or curtailing some phase III clinical trials for pixantrone and XYOTAX until planned regulatory filings and the completion of phase III studies result in product approvals. CTI expects to file for approval of XYOTAX in Europe in March. The Company will expand its commercial infrastructure for Zevalin and possible future drug sales while achieving an overall reduction in headcount.

"We believe the best way to maximize shareholder value now is to focus our resources on our marketed and late-stage products," noted James A. Bianco, M.D., President and CEO of CTI.

"Recently published data describing the clinical benefit of Zevalin are compelling and support the potential to expand its application into first-line treatment of follicular non-Hodgkin's lymphoma, leading us to expand our commercial operations staffing from 11 percent to 21 percent of our total headcount with corresponding reductions elsewhere. We will continue to support our two lead drug candidates, XYOTAX
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Reckitt Benckiser Completes Acquisition of Adams Respiratory Therapeutics, Inc.
2. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
3. Cell Therapeutics, Inc. Announces $6.5 Million Offering
4. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
5. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
6. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
7. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
8. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
9. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
10. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... Mabel’s Labels , the market ... an award-winning company established by four moms, today announced ... Tricia Mumby have been honored with a 2014 RBC ... PROFIT Award for Excellence in Entrepreneurship. , All 4 ... Mumby) accepted the award on behalf of Mabel’s Labels ...
(Date:11/28/2014)... Everett, WA (PRWEB) November 28, 2014 ... Snohomish County provides an overview of the influenza virus that ... annual flu season. , The article begins with a ... it manifests its symptoms. It reminds families that children under ... and those suffering from chronic diseases, such as heart and ...
(Date:11/28/2014)... FL (PRWEB) November 28, 2014 Lice Troopers ... areas of its in-home head lice service for moms ... in the center of Coral Gables on Pone De-leon Blvd ... Bay Harbor Islands that service Miami-Dade & Broward. Lice ... salon in South Florida which has been treating families for ...
(Date:11/28/2014)... Pittsburgh, PA (PRWEB) November 28, 2014 "Most ... have forced me to use crutches," said an inventor from ... better, more convenient way to support my foot, which inspired ... Foot Sling to offer a convenient way to support an ... to get around. It eliminates the need for crutches. The ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Schools ... value of providing quality commercial playground equipment to ... selected APCPLAY© to supply an affordable play structure ... City. , Centra provides comprehensive programs for ... and emotional support services. They have served ...
Breaking Medicine News(10 mins):Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2Health News:Lice Troopers Lice Removal Service Expands in Miami-Dade 2Health News:Centra Rivermont (VA) Provides School Playground Equipment from APCPLAY© for Special Needs Students 2Health News:Centra Rivermont (VA) Provides School Playground Equipment from APCPLAY© for Special Needs Students 3
... people newly diagnosed with HIV in the UK has ... with the transmission of antiretroviral-resistant HIV. // ... Protection Agency have investigated the connection between two phenomena: ... transmission, and the transmission of drug-resistant HIV. Sexually transmitted ...
... & Melinda Gates Foundation and the Medicines for Malaria ... center //in the United Arab Emirates (UAE). The center ... News reports. ,Gates Foundation and MMV representatives ... of Health to discuss the project. The foundation selected ...
... chances of contracting HIV by up to 60 percent, ... at increased risk of infection. // ,Early results ... potential impact of male circumcision on AIDS in Africa ... sex while healing from circumcision surgery, their female partners ...
... Dry Eye Syndrome (DES) has a significant impact on quality ... and 4.7% of men over 50, and affects over //4.8 ... have been identified, the cause of DES is still largely ... the quantity and/or quality of tears, an unstable tear film, ...
... and type 2 diabetes increases the risk of death for ... of heart disease deaths by itself, but together they’ve been ... an analysis of more than 900 patients with established coronary ... with both type 2 diabetes and symptoms of depression were ...
... of life are not sufficiently met and need to be upgraded ... systems do not reliably meet the needs of people living with ... and Joanne Lynn, two palliative care doctors based in the United ... we use language – and build health care systems – as ...
Cached Medicine News:Health News:STIs Significantly Increase Risk of Drug-resistant HIV Transmission 2Health News:Circumcision May Lift HIV Risk for Women 2Health News:Dry Eye Syndrome Affects Visual Functions 2Health News:Combination of Depression and Type-2-diabetes Lethal for Heart Patients 2Health News:Health Care Systems for Critically Ill Patients Need Restructuring 2
(Date:11/26/2014)... Texas , Nov. 26, 2014 ... today announced the completion of previously announced concurrent ... million.  After fees and estimated offering expenses, Lexicon ... the transactions.  The transactions consisted of: ... common stock, pursuant to a registration statement that ...
(Date:11/26/2014)... Calif. , Nov. 26, 2014  Avanir ... that the U.S. Food and Drug Administration (FDA) ... New Drug Application (NDA) for AVP-825. AVP-825 is ... sumatriptan powder delivered intranasally utilizing a novel Breath ... Complete Response letter, and consistent with the preliminary ...
(Date:11/26/2014)... 2014 Investor-Edge has initiated coverage on ... Horizon Pharma PLC (NASDAQ: HZNP ), Endocyte Inc. ... JNJ ), and Theravance Inc. (NASDAQ: THRX ... at: http://investor-edge.com/register . On Tuesday, November 25, ... Dow Jones Industrial Average edged 0.02% lower, to finish the ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... Sept. 18 A long-term study found,that a ... with life-threatening,diseases, such as leukemia and lymphoma, results ... males are likely to recover,from these changes over ... In addition, neither male nor female long-term cancer,survivors ...
... Bacterial Infection and May ... Bacterial Infections, BOSTON, Sept. 18 Paratek ... of the Company,s,Multiple Adaptation Response (MAR) inhibitor program. ... controlling virulence and antibiotic,resistance. Paratek has shown that ...
Cached Medicine Technology:Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 2Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 3Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 4Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 3Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 4
Serrated handle with polished finish. Non-magnetic. Straight tips: Delicate 11 mm. Most popular size or model....
Straight crisscross serrated tips. Flat handle with holes and polished finish....
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish....
5 mm tying platform, serrated cross action handle with polished finish. Teeth: 0.10 mm, 1 x 2 set at 90 degrees....
Medicine Products: